Key statistics
On Monday, TScan Therapeutics Inc (TCRX:NMQ) closed at 4.52, 15.31% above the 52 week low of 3.92 set on Nov 21, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.36 |
---|---|
High | 4.72 |
Low | 4.30 |
Bid | 4.50 |
Offer | 4.81 |
Previous close | 4.26 |
Average volume | 199.60k |
---|---|
Shares outstanding | 56.51m |
Free float | 51.80m |
P/E (TTM) | -- |
Market cap | 240.71m USD |
EPS (TTM) | -1.05 USD |
Data delayed at least 15 minutes, as of Nov 25 2024 21:00 GMT.
More ▼
- TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
- TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition
- TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting
- TScan Therapeutics to Participate in Upcoming Investor Conferences
- TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
- TScan Therapeutics Announces Updates to its Board of Directors
- TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
- TScan Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies
- TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
- TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors
More ▼